Researchers in the Roncarolo have discovered transcription factors that enable the tracking and differentiation of type 1 T regulatory (Tr1) cells for the treatment of autoimmune conditions.
Engineered cytotoxic T cells are a promising class of cell therapies. These living drugs are capable of selectively killing blood cancers, such as acute myeloid leukemia (AML), and delaying its progression.